Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
STAM binding protein like 1 (STAMBPL1)
- Target
- STAMBPL1
- Molecular classification
- Enzyme (deubiquitinase, metalloprotease), JAMM family zinc metalloprotease
01
Overview
STAM binding protein like 1 (STAMBPL1) is a zinc-dependent metalloprotease in the JAMM family, acting as a deubiquitinase with high specificity for Lys63-linked polyubiquitin chains. It regulates protein stability, degradation, and cell signaling—including the WNT/PI3K/NF-κB and TORC1 pathways—by removing ubiquitin from target proteins such as TRAF2 (tumor necrosis factor receptor-associated factor 2) and the EMT transcription factor SNAI1. STAMBPL1 is upregulated in several cancers, promoting cell proliferation, survival, and metastasis, and has been implicated as a novel biomarker and therapeutic target in oncology. Its depletion or inhibition can suppress EMT, enhance apoptosis, and reduce tumor growth, suggesting further therapeutic potential.
- Other names
- AMSH-like proteaseAMSHLPKIAA1373AMSH-LPAMSH-FPFLJ31524ALMalphabA399O19.2Associated molecule with the SH3 domain of STAM (AMSH)-like proteinAMSH-family protein
02
Mechanism of action
For potential inhibitors: Inhibiting deubiquitinase activity, leading to enhanced degradation of oncogenic proteins such as TRAF2 or SNAI1, promoting apoptosis and reducing metastasis
03
Biological functions
Deubiquitination (removal of Lys63-linked ubiquitin chains)Protein trafficking and signalingPositive regulation of TORC1 pathwayRegulation of cell survival and apoptosisPromotion of epithelial–mesenchymal transition (EMT) and metastasis
04
Disease associations
Cancer (notably hepatocellular carcinoma, colorectal, gastric, lung, breast, and prostate)Role in metastasis and tumor progressionPotential contribution to Aortic Aneurysm and Hermansky-Pudlak Syndrome 3 (associations reported)
05
Safety considerations
Targeting STAMBPL1 broadly may cause unintended effects on cell survival and stress response, affecting apoptosis regulationPotential systemic effects if deubiquitinase activity is inhibited in healthy tissues
06
Biomarkers
Elevated STAMBPL1 expression as a prognostic/predictive biomarker in several cancers, including HCC and gastric cancer
Beyond the preview
Go deeper on STAM binding protein like 1 (STAMBPL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAM binding protein like 1 (STAMBPL1).